主页 > 医药生命 >
【medical-news】葛兰素称更多政府计划购买禽流感
Glaxo says more govts plan to buy bird flu vaccine
Dr Garnier was appointed an Executive Director of SmithKline Beecham plc in 1992, and became Chief Executive Officer in April 2000. He is a... Full Bio
Full Management Team
Insider Trading Email This Article | Print This Article | Reprints [-] Text [+]
LONDON, Oct 26 (Reuters) - GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research) expects to sign more contracts to supply governments with its experimental bird flu vaccine for humans, following purchases by Switzerland and an unidentified Asian country.
"Between now and Christmas, I expect we will sign a few more in Europe and elsewhere," Chief Executive Jean-Pierre Garnier told analysts in a post-results conference call.
Europe's biggest drugmaker announced earlier this month that the Swiss Federal Office of Public Health had ordered 8 million doses of its H5N1 vaccine to protect its entire population in the event of an influenza pandemic, which many experts fear may be triggered by bird flu.
The vaccine has not yet won regulatory approval but Glaxo plans to file it with the European Medicines Agency by the end of 2006.
Glaxo's vaccine uses only a very low dose of active ingredient, which should help to stretch scarce supplies.
A key challenge in the race to produce a vaccine for millions of people around the world -- which governments are keen to stockpile -- is how to make the maximum number of shots from the minimum amount of antigen, or active ingredient.
While Glaxo's vaccine offers protection against the deadly H5N1 avian flu virus now circulating, its impact on any mutated strain of virus is not certain.
However, experts say it could "prime" an individual's immune system so they will get stronger effects from a later, better-matched vaccine.
The H5N1 strain of avian influenza has spread rapidly out of Asia and has killed more than 150 people who have come into close contact with infected birds.
Experts fear it could trigger a pandemic, a global epidemic of flu that could kill millions, if it acquires the ability to pass easily from human to human.
Rival companies including Sanofi-Aventis (SASY.PA: Quote, Profile, Research), Novartis AG (NOVN.VX: Quote, Profile, Research) and Baxter International Inc. (BAX.N: Quote, Profile, Research) are also racing to develop pandemic H5N1 vaccines.
© Reuters 2006. All Rights Reserved. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 葛兰素药厂称更多政府计划购买禽流感疫苗
Garnier博士1992年被任命为史克美占公司的常务董事 ，在2000年4月变成公司的执行总裁
伦敦，10月26日(路透通讯社)，葛兰素史克公司GSK在与瑞士和亚洲某国家签订了购买合同以后，期待签订更多的合同去支持各政府的人类禽流感研究实验。
Garnier博士在电话会议后分析到："从现在到圣诞节，我期待我们将和欧洲还有其他地方的国家签订更多购买合同"
欧洲最大的制药者宣布:瑞士公众健康联邦办公室月初已经预订了8，000，000万只H5N1疫苗去预防全民的流行性感冒(许多专家害怕禽流感触发的)
疫苗的作用虽然目前还没有得到验证，但是葛兰素药厂计划年底向欧盟药品管理局申请批准。
葛兰素药厂的疫苗使用了的非常低的最佳剂量的有效成分，这将有助于弥补这种药物的短缺。
在生产一种全世界几百万人使用的疫苗(政府热衷于储存)过程中，一个关键的挑战是怎样去使最小剂量的抗原或有效成分来使用于更多的人
虽然葛兰素药厂的疫苗使得人们在抵抗致死性H5N1禽流感的流行中受到保护，但是它病毒突变体的作用是不确定的
尽管如此，专家们说它能增强个人的免疫系统，使得更好的对病毒突变体的免疫抵抗
H5N1禽流感已经从亚洲国家中快速的蔓延到其他国家并且已经有超过150个人因近距离接触感染的禽类而死亡。
专家害怕这将可能导致恐慌，"如果它很容易在人和人之间传播，那将导致全球性的流行性感冒，几百万的人将因之而死"
与之竞争生产H5N1疫苗的公司有：赛诺菲-安万特公司，瑞士诺华公司，百特医疗用品有限公司 http://today.reuters.com/news/articleinvesting.aspx?view=CN&storyID=2006-10-26T150742Z_01_L26646731_RTRIDST_0_BIRDFLU-GLAXO-VACCINE.XML&rpc=66&type=qcna
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-27 17:44
医学,生命科学网